Oocyte Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.

Launched by WEST COAST FERTILITY CENTERS · Jul 14, 2008

Keywords

ClinConnect Summary

The cryopreservation of oocytes (OC) has broad applications in the field of reproductive endocrinology for the management of clinical problems in both fertile and infertile patients. For example, young fertile women who are diagnosed with malignancies may freeze their oocytes before initiating potentially toxic radiation or chemical cancer therapy which may render them sterile.

Using the OC technology, we have established a frozen oocyte bank using healthy, compensated egg donors who have been pre- screened using FDA criteria. Following an appropriate quarantine time, oocytes can be thawed...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• To be eligible for inclusion into this study, each subject must satisfy the following criteria:
• • 1. Participants must be aged 21 to 35 years
• • 2. Body mass index (BMI) \< 38.
• • 3. Serum results for cycle day 3 FSH \<10 mIU/ml.
• • 4. Be willing and able to comply with the protocol for the duration of the study.
• • 5. Have voluntarily provided written informed consent under WIRB, prior to any study-related procedure that is not part of normal medical care, with the understanding that the subjects may withdraw consent anytime without prejudice to their future medical care.
• • 6. Have passed a psychological and physical screening.
• Exclusion Criteria:
• A patient may NOT be entered into the study if she presents with ANY of the following criteria:
• • 1. Clinically significant systemic disease.
• • 2. Known endometriosis Grade III - IV (ASRM classification).
• • 3. Any previous cycle indicating a low response to gonadotropin stimulation (defined as retrieval of \< 10 eggs at retrieval)
• • 4. Previous ovarian surgery
• • 5. Known allergy or hypersensitivity to recombinant gonadotropin preparations or any other study-related medications.
• • 6. Known current substance abuse.
• • 7. Simultaneous participation in another clinical trial.
• • 8. Current smoker.
• • 9. An extrauterine pregnancy within the last 3 months before OCP treatment commences.
• • 10. Previous participation in similar study at different centers.